Athersys Inc (ATHXQ)

[dirkie]

How Healthy are Healthcare Companies: Complementary Research on Idera Pharma, Athersys Inc., Nevro Corp., Radius Health and OvaScience Inc.
13:40 (14/05) - Bron: PRN

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150514:enUK201505147878:1


NEW YORK, May 14, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.


Moments ago, Analysts Review released new research updates concerning several
important developing situations including Idera Pharmaceuticals, Inc. (NASDAQ:
IDRA), Athersys, Inc. (NASDAQ: ATHX), Nevro Corp. (NYSE: NVRO), Radius Health,
Inc. (NASDAQ: RDUS), and OvaScience, Inc. (NASDAQ: OVAS). Analysts Review
provides a single unified platform for investors' to hear about what matters -
proudly employing registered CFA research staff and rigorous compliance
procedures. The full research reports are being made available to the public for
informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links
below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into
your browser):

IDRA Research Report: (
http://get.analystsreview.com/pdf/?c=Idera%20Pharmaceuticals&d=14-May-2015&s=IDRA
),

ATHX Research Report: (
http://get.analystsreview.com/pdf/?c=Athersys&d=14-May-2015&s=ATHX ),

NVRO Research Report: (
http://get.analystsreview.com/pdf/?c=Nevro%20Corp&d=14-May-2015&s=NVRO ),

RDUS Research Report: (
http://get.analystsreview.com/pdf/?c=Radius%20Health&d=14-May-2015&s=RDUS ),

OVAS Research Report: (
http://get.analystsreview.com/pdf/?c=OvaScience&d=14-May-2015&s=OVAS ).

============

--

Analyst Update: Earnings Update, Regulatory Approval

U.S. stocks closed virtually flat on Wednesday, amid disappointing monthly
retail sales data. The Dow Jones Industrial Average fell 0.04%, to finish at
18,060.49, the S&P 500 edged down 0.03%, to 2,098.48, while the NASDAQ Composite
rose modestly by 0.11%, to end the session at 4,981.69. European stocks mostly
closed lower on Wednesday, despite positive economic growth data. Germany's
DAX 30 declined 1.05%, and France's CAC 40 slipped 0.26%. In contrast,
London's FTSE 100 closed 0.23% higher on Wednesday, mainly reflecting upbeat
unemployment data. Meanwhile, Asian markets were mixed on Wednesday, amid weaker
Chinese economic data. The Shanghai Composite and Hong Kong's Hang Seng were
both down on Wednesday, while Japan's Nikkei closed higher.

On May 11, 2015, Idera Pharmaceuticals, Inc. reported its financial and
operational results for Q1 FY15. Revenue rose to $34,000 in Q1 FY15 from
$3,000 in Q1 FY14. Net loss applicable to common stockholders for Q1 FY15 was
$12.5 million, or $0.12 per diluted share, compared to $9.1 million, or
$0.12 per diluted share, for the same period in 2014.

On May 11, 2015, Athersys, Inc. announced its Q1 FY15 results. Revenue rose by
3.4% to $0.73 million in Q1 FY15 from $0.71 million in Q1 FY14. R&D expenses
were $5.7 million for the first quarter of 2015 compared to $6.2 million for
the prior-year period.

On May 8, 2015, Nevro Corp., a medical device company that provides solutions
for the treatment of chronic pain, announced that it has received approval from
the United States Food and Drug Administration (FDA) for its Senza spinal cord
stimulation (SCS) system.

On May 6, 2015, Radius Health, Inc. announced its Q1 FY15 results. Net loss for
Q1 FY15 was $17.1 million, or $0.47 per share, as compared to a net loss of
$14.5 million, or $50.45 per share for Q1 FY14.

OvaScience reported its Q1 FY15 financial results on May 11, 2015. Net loss for
the quarter was $17.2 million, or $0.65 per share, as compared to net loss of
$7.8 million, or $0.41 per share, for the same period in 2014.

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and analysis of
the complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information
available, we have set ourselves apart as one of the premier online investor
communities.

--

Editor Note: This is not company news. We are an independent source and our
views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a
best-effort basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider, represented by a
registered analyst has only reviewed the information provided by Analysts Review
in this article or report according to the procedures outlined by Analysts
Review. Analysts Review is not entitled to veto or interfere in the application
of such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

Further Resources: For more information about this release including editorial
notes, compliance procedures and legal disclosures, please visit:
http://www.analystsreview.com/editors

CFA and Chartered Financial Analyst are registered trademarks owned by CFA
Institute.

SOURCE Analysts Review


Adam Redford
CONTACT PHONE: [phone]

Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved.